Cytomegalovirus infection and disease in pediatric liver transplantation: Burden of disease under a preemptive therapy approach

被引:3
作者
Arroyo-Orvananos, Jorge [1 ]
Hernandez-Plata, Jose-Alejandro [1 ]
Erro-Aboytia, Rosa [1 ]
Nieto-Zermeno, Jaime [1 ]
Reyes-Lopez, Alfonso [1 ]
Varela-Fascinetto, Gustavo [1 ]
机构
[1] Hosp Infantil Mexico Dr Federico Gomez, Transplantat Dept, Doctor Marquez 162, Mexico City 06720, DF, Mexico
关键词
CMV; CMV disease; CMV infection; pediatric liver transplant; preemptive therapy; PREVENTION; PROPHYLAXIS; STRATEGIES; MANAGEMENT;
D O I
10.1111/petr.14356
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background CMV remains a frequent complication after liver transplantation. Few studies exist in children reporting the epidemiology and outcomes of CMV after LT with current prevention strategies. Our goal is to report the incidence of CMV infection and disease in pediatric LT recipients under preemptive therapy, identify risk factors, complications, and adverse reactions to treatment. Methods All pediatric LT recipients from a single center (1998-2018) were included. Antigenemia pp65 (1998-2003) and QNAT or both were used to inform preemptive therapy. Cutoff value for starting treatment was Agpp65 > 10 + cells/200 000 or QNAT >1500 copies/ml or any value in high-risk recipients (D+/R-). Results One hundred eighteen LT were analyzed. CMV infection was detected in 67% of patients, only 44 (37%) required treatment, and 5 (4%) developed CMV disease. All patients responded well to treatment, and no graft or patients were lost to CMV effects. There were no differences in mortality, CMV indirect effects, or other complications between those who required treatment and those who did not. Thirty-two percent of the patients who received antivirals developed an adverse hematological reaction. Risk factors associated with CMV infection requiring treatment were D+/R- (OR 13.9, p = .01) and fulminant hepatitis (OR 4.8, p = .02). Conclusions Preemptive therapy for CMV in children is safe and effective, yields low CMV infection rates that require treatment, and minimal rates of CMV disease, without increasing CMV-related complications. Using this strategy, 63% of our patients did not receive treatment. Therefore, drug exposure, adverse reactions, and resistance risk were minimized.
引用
收藏
页数:8
相关论文
共 18 条
[1]   Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: Comparison of prophylactic oral ganciclovir and oral valganciclovir [J].
Bedel, Ashley N. ;
Hemmelgarn, Trina S. ;
Kohli, Rohit .
LIVER TRANSPLANTATION, 2012, 18 (03) :347-354
[2]   Management of cytomegalovirus infection and disease in liver transplant recipients [J].
Bruminhent, Jackrapong ;
Razonable, Raymund R. .
WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (06) :370-383
[3]   Current Prevention Strategies Against Cytomegalovirus in the Studies in Pediatric Liver Transplantation (SPLIT) Centers [J].
Danziger-Isakov, L. ;
Bucavalas, J. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (08) :1908-1911
[4]   Fulminant Hepatic Failure as a Risk Factor for Cytomegalovirus Infection in Children Receiving Preemptive Therapy After Living Donor Liver Transplantation [J].
Furuichi, Munehiro ;
Fujiwara, Takeo ;
Fukuda, Akinari ;
Kasahara, Mureo ;
Miyairi, Isao .
TRANSPLANTATION, 2016, 100 (11) :2404-2409
[5]   Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation [J].
Gerna, Giuseppe ;
Lilleri, Daniele ;
Callegaro, Annapaola ;
Goglio, Antonio ;
Cortese, Serena ;
Stroppa, Paola ;
Torre, Giuliano .
TRANSPLANTATION, 2008, 86 (01) :163-166
[6]   Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients [J].
Hodson, Elisabeth M. ;
Ladhani, Maleeka ;
Webster, Angela C. ;
Strippoli, Giovanni F. M. ;
Craig, Jonathan C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02)
[7]  
Honar, 2011, SO IRAN INT J ORGANT, V2, P20
[9]   PROSPECTIVE CYTOMEGALOVIRUS SURVEILLANCE IN PEDIATRIC RENAL-TRANSPLANT PATIENTS [J].
IRAGORRI, S ;
PILLAY, D ;
SCRINE, M ;
TROMPETER, RS ;
REES, L ;
GRIFFITHS, PD .
PEDIATRIC NEPHROLOGY, 1993, 7 (01) :55-60
[10]   Risk Factors of Cytomegalovirus Infection After Pediatric Liver Transplantation [J].
Kawano, Y. ;
Mizuta, K. ;
Sanada, Y. ;
Urahashi, T. ;
Ihara, Y. ;
Okada, N. ;
Yamada, N. ;
Sasanuma, H. ;
Sakuma, Y. ;
Taniai, N. ;
Yoshida, H. ;
Kawarasaki, H. ;
Yasuda, Y. ;
Uchida, E. .
TRANSPLANTATION PROCEEDINGS, 2014, 46 (10) :3543-3547